ライフサイエンスコーパス: DPP

1 DPP appears to be synthesized as a part of a larger comp

2 DPP IV is responsible of the degradation of the incretin

3 DPP lifestyle modification programs achieved clinically

4 DPP nontreponemal line sensitivity was 94.2% (95% CI, 91

5 DPP test outcome (pair of test lines) was concordant wit

6 DPP test use would result in identification of >93% of a

7 DPP was similar in the 2 groups, and proportions of pati

8 DPP-4 inhibition reduced glycemia and enhanced insulin l

9 DPP-4 inhibition with saxagliptin did not increase or de

10 DPP-4 inhibitors expand beta-cell mass, reduce alpha-cel

11 DPP-4 inhibitors were associated with lower risks for al

12 DPP-IV activity in cHSA was compared with other sources

13 DPP-IV activity was assayed at 37 and 60 degrees C becau

14 DPP-IV inhibitory peptide sequences identified within ca

15 single policy studied (approximately 230,000 DPPs by 2030) while also significantly reducing disparit

16 ligible individuals, by approximately 8% (10 DPPs per 100,000 population).

17 on of villin by 29% (6%), Cdx2 by 31% (10%), DPP-4 by 15% (6%), GLUT2 by 40% (11%), SLFN12 by 61% (14

18 approximately 31,000 (95% UI 26,800-35,300) DPPs for a 10% SSB tax.

19 inedione (SMD, 0.16 [95% CI, 0.00 to 0.31]), DPP-4 inhibitor (SMD, 0.33 [95% CI, 0.13 to 0.52]), and

20 Sequence alignment of 39 DPP-IV inhibitory peptides having IC50's<200 muM reveale

21 erapeutic effects of dipeptidyl peptidase 4 (DPP-4) inhibition (vildagliptin) by using the GLP-1 rece

22 potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excellent pharmacokinetic profi

23 uding saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

24 sed drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) an

25 , a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2

26 orter 2 (GLUT2), and dipeptidyl peptidase 4 (DPP-4), as well as that of the putative differentiation

27 nzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and through renal clearance.

28 ts and inhibitors of dipeptidyl peptidase-4 (DPP-4) have shown pleiotropic effects on bone metabolism

29 o had baseline serum dipeptidyl peptidase-4 (DPP-4) higher than the population baseline median, we no

30 4 patients with T2D, dipeptidyl peptidase-4 (DPP-4) inhibition and its glucose-lowering actions were

31 GAT1 inhibition with dipeptidyl-peptidase-4 (DPP-4) inhibition led to further enhancements in active

32 as as effective as a dipeptidyl peptidase-4 (DPP-4) inhibitor at reducing peak glucose levels in an a

33 Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use against type 2 diabetes

34 Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibitor that inhibits the degradation of glucag

35 In this regard, dipeptidyl peptidase-4 (DPP-4) inhibitors have recently been reported to attenua

36 glucose lowering by dipeptidyl peptidase-4 (DPP-4) inhibitors is unclear.

37 Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent degradation of incretin hormon

38 udies concluded that dipeptidyl peptidase-4 (DPP-4) inhibitors provide glycemic control but also rais

39 GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors represent 2 distinct classes of incret

40 ones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (S

41 hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating uncertainty about the safety

42 ists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inact

43 ion by inhibition of dipeptidyl peptidase-4 (DPP-4) promotes glycemic reduction for the treatment of

44 s, and inhibition of dipeptidyl peptidase-4 (DPP-4), which cleaves GLP-1, is renoprotective in rodent

45 are both cleaved by dipeptidyl peptidase-4 (DPP-4); hence, inhibition of DPP-4 activity enables yet

46 approximately 25,800 (95% UI 24,300-28,500) DPPs for a 1-y MMC, or the approximately 31,000 (95% UI

47 approximately 35,100 (95% UI 31,700-37,500) DPPs potentially attributable to a 30% F&V subsidy targe

48 The model takes 68 DPP-IV inhibitory peptides (having an IC50 value <2000 m

49 reducing disparities, by approximately 6% (7 DPPs per 100,000 population).

50 Fully 70 to 80% DPP-IV activity remained at 60 degrees C compared with t

51 half the effect seen with the addition of a DPP-4 inhibitor, and equated to a dose difference of 550

52 The power conversion efficiency (PCE) of a DPP-based polymer solar cell is significantly improved b

53 n successfully applied to the synthesis of a DPP-IV inhibitor and a variety of other amines.

54 thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control

55 Treatment with a DPP-4 inhibitor, alogliptin (AG), significantly reduced

56 effects on cardiovascular outcomes of adding DPP-4 inhibitors versus sulfonylureas to metformin thera

57 In addition, DPP and annexin 2 colocalize in the ureteric bud branche

58 munostaining for phospho-MAD (Mother against DPP), a downstream effector of Dpp function.

59 on at 7.0 displayed higher ORAC activity and DPP-IV inhibitory properties compared to the associated

60 advances that reveal how GLP-1R agonists and DPP-4 inhibitors affect the normal and diabetic heart an

61 es demonstrate that both GLP-1R agonists and DPP-4 inhibitors exhibit cardioprotective actions in ani

62 ardiovascular actions of GLP-1R agonists and DPP-4 inhibitors, with a focus on the translation of mec

63 Urinary concentrations of BDCPP and DPP were moderately to highly reliable within individual

64 for unequal amounts of intracellular DSP and DPP.

65 od was collected for analysis of glucose and DPP-4 levels.

66 PP was detected in 91% of urine samples, and DPP in 96%.

67 ox models with exposure to sulfonylureas and DPP-4 inhibitors included as time-varying covariates wer

68 Val to the secondary binding sites of XO and DPP-IV is required.

69 ates of in-hospital heart failure in another DPP-4 inhibitor trial have been reported.

70 aintenance of target gene domains as well as DPP's role in growth control.

71 nefits over currently commercially available DPP-4 inhibitors, MK-3102 (omarigliptin), was identified

72 GLP-1 signaling is unclear, however, because DPP-4 cleaves other molecules as well.

73 interaction between expansion and TGF-beta (DPP) signaling was observed.

74 e transforming growth factor-beta (TGF-beta, DPP) signaling pathway.

75 dominant negative plasmid of CaMKII, blocked DPP-mediated Smad1 phosphorylation.

76 The cardiovascular mechanisms engaged by DPP-4 inhibition are more complex, encompassing increase

77 -36), a cardioactive metabolite generated by DPP-4-mediated cleavage.

78 The majority of angioedema induced by DPP IV inhibitors occurs during concomitant treatment wi

79 an be committed to the osteogenic lineage by DPP.

80 aQuick Advance Rapid HIV-1/2 and the Chembio DPP HIV-1/2) from May to September 2009 in two CT sites

81 The Chembio DPP OF test showed 519 (31.0%) reactive samples and 1,15

82 d that the binding energies of Zn-DPP and Co-DPP are significantly higher than those of Ni-DPP and Cu

83 ides were synthesized and exhibited complete DPP-IV resistance and enhanced in vitro insulin secretio

84 , blends of the narrow optical gap copolymer DPP-DTT with PC70BM show two distinct spectrally flat re

85 ificantly higher than those of Ni-DPP and Cu-DPP.

86 uch as the TGF-beta homolog Decapentaplegic (DPP).

87 In this paper, we show that Decapentaplegic (DPP) and JNK form a coherent FFL that controls the speci

88 in addition to being present in the dentin, DPP is also present in nonmineralizing tissues like the

89 The most potent camel milk protein-derived DPP-IV inhibitory peptides, LPVP and MPVQA, had DPP-IV h

90 ith zwitterion-substituted dibromothiophene, DPP, and NDI monomers by A2 + B2 Suzuki polymerization.

91 harge generation for a total of 16 different DPP polymers, we confirm that the minimal driving force,

92 monly reported materials, but also difuranyl-DPP, diselenophenyl-DPP and dithienothienyl-DPP-containi

93 yl]tellurophene with a diketopyrrolopyrrole (DPP) monomer.

94 ment, furan-containing diketopyrrolopyrrole (DPP) polymers with similar optoelectronic properties wer

95 methene (BODIPY) dyes, diketopyrrolopyrrole (DPP) dyes, and electron donor fragments based on triaryl

96 ects are found in many diketopyrrolopyrrole (DPP)-based copolymers reported in the literature.

97 ur different 2-pyridyl diketopyrrolopyrrole (DPP) polymer-fullerene solar cells.

98 ontaining thiophene-, diketopyrrolopyrrole- (DPP), and naphthalene diimide (NDI) backbones, were synt

99 Dipeptidylpeptidase (DPP) 4 has the potential to truncate proteins with a pen

100 t transistor applications including diphenyl-DPP and dithienyl-DPP-based polymers as the most commonl

101 In our effort to discover DPP-4 inhibitors with added benefits over currently comm

102 ials, but also difuranyl-DPP, diselenophenyl-DPP and dithienothienyl-DPP-containing polymers.

103 -DPP, diselenophenyl-DPP and dithienothienyl-DPP-containing polymers.

104 cations including diphenyl-DPP and dithienyl-DPP-based polymers as the most commonly reported materia

105 posed of 3 parts: dentin sialoprotein (DSP), DPP, and dentin glycoprotein (DGP).

106 The morphology of the DT-DPP:[70]PCBM blends is characterized by a semicrystallin

107 The high molecular weight DT-DPP polymers were incorporated in bulk heterojunction so

108 for the degradation of the non-electroactive DPP into phenol, which is directly measured by differenc

109 cHSA was assayed for DPP-IV activity using a specific DPP-IV substrate and in

110 ICCs for DPP were lower, but moderately reliable (range, 0.35-0.5

111 hydrogen microbubbles and hydroxyl ions for DPP degradation.

112 The classical mechanism for DPP-4 inhibitors is that they inhibit DPP-4 activity in

113 humans have found additional mechanisms for DPP-4 inhibitors that may contribute to their glucose-lo

114 17.9 10(-6) muM(-1)g(-1)), respectively for DPP-IV inhibitory peptides.

115 The results were similar for DPP-4 inhibitors and GLP-1 analogues.

116 Utilizing a DSS polypeptide derived from DPP, we demonstrate the repetitive DSS-rich domain facil

117 Furthermore, DPP-4 inhibition rescued WD-induced decreases in hepatic

118 Es) of about 5%, while the narrow-energy-gap DPP- and NDI-based CPZs performed exceptionally well, gi

119 ical mechanisms include 1) inhibition of gut DPP-4 activity, which prevents inactivation of newly rel

120 -IV inhibitory peptides, LPVP and MPVQA, had DPP-IV half maximal inhibitory concentrations (IC50) of

121 The highest DPP-IV inhibitory activity was found with the amino acid

122 also highlight outstanding questions of how DPP coordinates patterning and growth during development

123 om studies in the United States implementing DPP lifestyle modification programs (focused on modest [

124 tor changes observed in studies implementing DPP interventions in nonresearch settings in the United

125 ss (agreement: 85.0% in Look AHEAD; 87.4% in DPP).

126 ss (agreement: 91.6% in Look AHEAD; 90.5% in DPP).Although all of the criteria discriminated on the b

127 e serology (T1 and T2) to monitor changes in DPP optical density (using an automatic reader) at 3 and

128 : 6.6-11.9 kg in Look AHEAD; 11.5-14.6 kg in DPP; P < 0.0001).

129 sm for DPP-4 inhibitors is that they inhibit DPP-4 activity in peripheral plasma, which prevents the

130 ted the feasibility of using mAbs to inhibit DPP-IV activity and to improve glucose tolerance in a di

131 Leu, Val-Ala, Ser-Leu and Gly-Leu) inhibited DPP-IV.

132 ch for an alternative strategy of inhibiting DPP-IV activity, we generated a panel of tight binding i

133 G-CSF), a dipeptidyl peptidase IV inhibitor (DPP-4i), and a proton pump inhibitor (PPI).

134 rtal GLP-1 receptors; 2) inhibition of islet DPP-4 activity, which prevents inactivation of locally p

135 oline-specific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed in mammalians, re

136 roteases, including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8 (DPP8), fibroblast activ

137 Dipeptidyl peptidase IV (DPP-IV) degrades the incretin hormone glucagon-like pept

138 ne oxidase (XO) and dipeptidyl peptidase IV (DPP-IV) inhibition by amino acids and dipeptides was stu

139 ng enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory and oxygen radical absorbance capacit

140 Nine novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (FLQY, FQLGASPY, ILDKEGIDY,

141 mise the release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides during hydrolysis of bovine

142 act as a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.

143 of pH regulation on dipeptidyl peptidase IV (DPP-IV) properties.

144 to act as preferred dipeptidyl peptidase IV (DPP-IV) substrates.

145 uch as the protease dipeptidyl peptidase IV (DPP-IV), possibly contribute to the therapeutic effect o

146 tivities, including dipeptidyl peptidase-IV (DPP-IV) and angiotensin converting enzyme I (ACE) inhibi

147 apid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

148 apid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

149 ecific dipeptidyl aminopeptidase IV (DPP IV, DPP-4, CD26), widely expressed in mammalians, releases X

150 roperties of M(II)-5,15-diphenylporphyrin (M-DPP) single-molecule junctions (M=Co, Ni, Cu, or Zn diva

151 ht was reduced or maintained with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 in

152 particular through a pivotal monosubstituted DPP building block with a reactive bromo substituent.

153 New DPP dyes are conveniently prepared from commercially ava

154 ounterparts, ranging from 2.10(-2) G0 for Ni-DPP up to 8.10(-2) G0 for Zn-DPP.

155 PP are significantly higher than those of Ni-DPP and Cu-DPP.

156 No DPP-IV activity was present in rHSA, suggesting that DPP

157 f the six collected fractions showed notable DPP-IV inhibitory activity.

158 Camel milk proteins contain novel DPP-IV inhibitory peptides which may play a role in the

159 Three novel DPP-IV inhibitory peptides, Ile-Leu-Ala-Pro, Leu-Leu-Ala

160 This progress report summarizes the numerous DPP-containing polymers recently developed for field-eff

161 ccessfully applied to the direct analysis of DPP in selected food and biological samples, without any

162 tagliptin reduced the serum concentration of DPP-4.

163 ay provide an impetus for the development of DPP-4 inhibitors for the prevention and treatment of str

164 erall, we demonstrate that the DSS domain of DPP functions as a novel cell-penetrating peptide, and t

165 blood glucose is impaired; 2) the effect of DPP-4 inhibition on glycemia is likely to depend on adeq

166 blockade, whereas the inhibitory effects of DPP-4 inhibition on glucagon and GE were abolished.

167 antagonist, the glucose-lowering effects of DPP-4 inhibition were reduced by approximately 50%.

168 es GLP mediating the antidiabetic effects of DPP-4 inhibition.

169 pic effects may contribute to the effects of DPP-4 inhibition.

170 significantly to the therapeutic effects of DPP-4 inhibition.

171 Examinations of DPP- and gingipain gene-disrupted mutants indicated that

172 Several families of DPP IV inhibitors have been synthesized and evaluated.

173 The function of DPP has been studied at multiple levels: ranging from th

174 We propose that the main function of DPP pathway during Drosophila DC is to ensure robust mor

175 rsed in vitro and in vivo by inactivation of DPP-3 and TOP-1.

176 yl peptidase-4 (DPP-4); hence, inhibition of DPP-4 activity enables yet another pathway for potentiat

177 ivation of GLP-1R signaling or inhibition of DPP-4 activity produces a broad range of overlapping and

178 LP-1 system by pharmacological inhibition of DPP-4 caused hyperinsulinemia, suppression of glucagon r

179 hibitor of XO and a competitive inhibitor of DPP-IV.

180 ovascular drug classes, namely inhibitors of DPP IV or neprilysin, have been developed.

181 Significant levels of DPP-IV activity were present in cHSA.

182 d discusses these nonclassical mechanisms of DPP-4 inhibition.

183 Different modes of DPP-IV inhibition were observed depending on the test co

184 of 10,089 propensity score-matched pairs of DPP-4 inhibitor users and sulfonylurea users were examin

185 ments during the translational regulation of DPP.

186 f food proteins for the enzymatic release of DPP-IV inhibitory peptides.

187 l of beta-lactoglobulin as natural source of DPP-IV inhibitory peptides.

188 heat were identified as potential sources of DPP-IV inhibitory peptides.

189 Three stereoisomers of DPP(TBFu)2 are separated and identified to investigate t

190 ogical functions and potential substrates of DPP IV enzymes are reviewed and the characteristics of t

191 the DSPP gene that directs the synthesis of DPP.

192 e daily, such as liraglutide, and the use of DPP-IV inhibitors in the management of type 2 diabetes.

193 trials, along with the potential utility of DPP-4 and periostin as biomarkers of interleukin-13 path

194 nt publications that both enrich our view of DPP signaling but also highlight outstanding questions o

195 Our results indicate that the wiring of DPP signaling buffers against environmental challenges a

196 erature and time had a significant effect on DPP-IV inhibitory properties (p<0.05) in contrast with E

197 Rates of diastolic OPP (DPP)</=50, </=40, </=30 mmHg in the 2 groups were calcul

198 e CP-induced increase in the levels of other DPP-4 substrates such as stromal cell-derived factor-1 a

199 The dipeptidyl peptidase (DPP) 4 family includes four enzymes, DPP4, DPP8, DPP9 an

200 Dipeptidyl peptidase (DPP)-4 inhibition is a glucose-lowering treatment for ty

201 and thermodynamics of dipeptidyl peptidase (DPP)-4 inhibitors (gliptins) were investigated using sur

202 Dipeptidyl peptidase (DPP)-IV inhibitory peptides were purified and identified

203 y against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PRE

204 for FAP over both the dipeptidyl peptidases (DPPs), with which it shares exopeptidase specificity, an

205 processes mediated by dipeptidyl-peptidases (DPPs) should be beneficial for the organism.

206 Two new high-performance DPP-containing donor molecules employing a molecular arc

207 l) phosphate (BDCPP) and diphenyl phosphate (DPP), metabolites of the OPFRs tris(1,3-dichloro-2-propy

208 ysis of the anion of di-2-pyridyl phosphate (DPP) is thousands of times faster (ca. 3000 at 100 degre

209 dy we demonstrate that dentin phosphophoryn (DPP) is internalized by several cell types via a non-con

210 ne-rich protein called dentin phosphophoryn (DPP).

211 Dentin phosphoprotein (DPP) is the most abundant noncollagenous protein in the

212 lycoprotein (DGP) and dentin phosphoprotein (DPP).

213 direct determination of diphenyl phthalate (DPP) in food and biological samples is presented.

214 point-of-care assay-the Dual Path Platform (DPP) syphilis assay, which is based on simultaneous dete

215 -158,500) CVD deaths prevented or postponed (DPPs) by 2030 in the US.

216 fluorinated biomolecules including a potent DPP-II inhibitor and acyclonucleoside analogues as poten

217 , ranging from strong stallers, such as PPP, DPP, and PPN to weak stallers, such as CPP, PPR, and PPH

218 esign by extracting depth-position profiles (DPP) of the central sulcus (CS).

219 By using dynamic proteome profiling (DPP), we investigated the contribution of both synthesis

220 The Diabetes Prevention Program (DPP) study showed that weight loss in high-risk adults l

221 icipants of the Diabetes Prevention Program (DPP) with genetic consent.

222 rofiling in the Diabetes Prevention Program (DPP), a completed trial that randomized high-risk indivi

223 Within the Diabetes Prevention Program (DPP), a trial for the prevention of type 2 diabetes amon

224 mpared with the Diabetes Prevention Program (DPP), decreased in the placebo (-42%) and metformin (-25

225 d data from the Diabetes Prevention Program (DPP), we examined power in conventional and genotype-bas

226 ; n = 1791) and Diabetes Prevention Program (DPP; n = 613) participants with >/=3% initial weight los

227 ype 2 diabetes (Diabetes Prevention Program [DPP]; N = 917/907 intervention/comparison) or with type

228 mmercially available diketo-pyrrolo-pyrrole (DPP) pigments Irgazin Ruby and Irgazin Scarlet.

229 use monoclonal antibodies (mAbs) against rat DPP-IV.

230 d here matches with previous data on related DPP-based polymers.

231 re settings (median, $424) than for the U.S. DPP (Diabetes Prevention Program) trial and the DPP Outc

232 Aligned films of a semiconducting DPP-based copolymer exhibit highly anisotropic charge tr

233 Presently, several DPP IV inhibitors, the "gliptins", are approved for type

234 simulated gastrointestinal digestion (SGID, DPP-IV IC50=0.60+/-0.06vs.

235 Thus, a significant DPP-4-sensitive glucose-lowering mechanism contributes t

236 urrently implemented RPR test to the simpler DPP assay could ease the implementation of yaws eradicat

237 f exenatide (GLP-1 agonist) and sitagliptin (DPP-4 inhibitor) during periodontitis induction by ligat

238 This activity was abolished using a specific DPP-IV inhibitor.

239 assayed for DPP-IV activity using a specific DPP-IV substrate and inhibitor.

240 Compared with sulfonylureas, DPP-4 inhibitors were associated with lower risks for al

241 ioavailability of functional foods targeting DPP-IV inhibition with potential blood glucose regulator

242 Among 1005 serum samples tested, DPP treponemal line sensitivity was 89.8% (95% confidenc

243 unction approaches, we also demonstrate that DPP is essential for the formation of well-defined tooth

244 Further, we provide evidence that DPP is transported to the extracellular matrix (ECM) thr

245 nd metformin-based combinations, except that DPP-4 inhibitors had smaller effects.

246 In this report, we show that DPP binds to annexin 2 and 6 present in a rat ureteric b

247 These findings suggest that DPP is capable of triggering commitment of pluripotent s

248 These studies suggest that DPP-4 inhibition ameliorates hepatic steatosis and insul

249 ctivity was present in rHSA, suggesting that DPP-IV activity is present only in HSA produced using th

250 we provide evidence for the first time that DPP-IV activity contributes to the formation of aspartat

251 We argue that DPPs are powerful phenotypes that should inform genetic

252 The DPP assay is accurate for identification of antibodies t

253 The DPP T1 (treponemal) assay had a sensitivity of 88.4% (95

254 The DPP T2 (non-treponemal) assay had a sensitivity of 87.9%

255 The DPP-4 inhibitor prevented WD-induced hepatic steatosis a

256 The DPP-IV half maximal inhibitory concentration (IC50) of H

257 festyle intervention over 4 years across the DPP and Look AHEAD.

258 ver CS depth ranged from 1 to 50% across the DPP.

259 (Diabetes Prevention Program) trial and the DPP Outcomes Study ($5881).

260 senatide in Acute Coronary Syndrom]) and the DPP-4 inhibitors saxagliptin (SAVOR-TIMI 53 trial [Saxag

261 hat through repression by Brinker (Brk), the DPP branch of the FFL filters unwanted JNK activity.

262 ose Western diet (WD) or a WD containing the DPP-4 inhibitor, MK0626, for 16 weeks.

263 nor impact on the device performance for the DPP- and NDI-CPZs, a finding attributed to their electro

264 This approach was examined in the DPP (Diabetes Prevention Program) and the DPPOS (Diabete

265 mates and allele frequencies reported in the DPP for the rs8065082 SLC47A1 variant, a metformin trans

266 hange in ISI over 1 year of follow-up in the DPP intervention (metformin and lifestyle) and control (

267 omparisons in Look AHEAD and 13 of 28 in the DPP were in high agreement.

268 Ninety proteins were included in the DPP, with 28 proteins exhibiting significant responses t

269 metformin groups compared with those in the DPP.

270 lated the sensitivity and specificity of the DPP assay for detection of antibodies to treponemal (T1)

271 are reviewed and the characteristics of the DPP IV inhibitors are discussed in view of type 2 diabet

272 The metal ion in the center of the DPP skeletons is strongly coordinated with the nitrogens

273 re of 1:8 or greater, the sensitivity of the DPP T2 assay was 94.1% (95% CI 89.9-96.9).

274 EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to placebo on major adverse c

275 ews the most recent CV outcome trials of the DPP-4 inhibitors (SAVOR-TIMI 53, EXAMINE, and TECOS) as

276 goal was to ascertain at what timepoint the DPP assay line reverted to negative after treatment.

277 the thiophene donor of one molecule with the DPP core acceptor in another molecule as observed in the

278 ovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo.

279 DA-DKP at 60 degrees C was observed with the DPP-IV inhibitor significantly decreasing this formation

280 ciated with weight loss or regain within the DPP and Look AHEAD trials, directly or via interactions

281 h-throughput live imaging revealed that this DPP/Brk branch is dispensable for DC under normal condit

282 mploying a molecular architecture with three DPP chromorphores (tri-DPP) in conjugated backbones are

283 iptin increased intact GLP-1 and GIP through DPP-4 inhibition but reduced total GLP-1 and GIP (feedba

284 Binding of gliptins to DPP-4 is a rapid electrostatically driven process.

285 (5.6 +/- 1.7 mmol/mol) lower A1C response to DPP-4 inhibitor treatment in G-allele carriers, but ther

286 ay, development of diabetes, and response to DPP-4 inhibitor treatment.

287 chitecture with three DPP chromorphores (tri-DPP) in conjugated backbones are synthesized and charact

288 The two tri-DPP molecules with only a structural difference on alkyl

289 sH were prodrug- while WPH and LFH were true DPP-IV inhibitors.

290 activity was found with the amino acid Tyr (DPP-IV IC50=75.15+/-0.84muM).

291 G) content was significantly attenuated with DPP-4 inhibitor treatment.

292 al inhibition, and suggests combination with DPP-4i as a potential strategy to develop DGAT1 inhibito

293 The risk for hHF was not higher with DPP-4 inhibitors than with the other study drugs.

294 gastrointestinal enzymes were incubated with DPP-IV at 37 degrees C for 18 or 24h.

295 akdown was evident following incubation with DPP-IV.

296 Several peptides with DPP-IV inhibitory features or known activity were identi

297 t 2 Australian laboratories were tested with DPP Screen and Confirm Assay.

298 lin excursion after an OGTT with and without DPP-4 inhibition.

299 0(-2) G0 for Ni-DPP up to 8.10(-2) G0 for Zn-DPP.

300 with its higher conductance, we identify Zn-DPP as the favoured candidate for high-conductance CPP s

301 We find that the binding energies of Zn-DPP and Co-DPP are significantly higher than those of Ni